CAS: 24818-79-9; Aluminium Hydroxide 2-(4-Chlorophenoxy)-2-Methylpropanoate (1:1:2 )

该化合物是一种化学化合物,属于被称为纤维化物的药物类别,主要用于管理血液中的脂肪含量,其特征是能够降低三氟化物水平,增加高密度脂质脂蛋白胆固醇,该化合物是硫化物的复合体,是氯苯氧基丁酸酯的酯,铝的二氟化硫表现出铝盐和纤维化物的典型特性,包括潜在的抗炎效应,经常研究其药理学应用,特别是在糖尿病和代谢紊乱的情况下,该化合物通常以受控剂量的形式进行,并可能具有与铝接触和纤维化疗法有关的副作用,例如气态肠紊乱或与肌肉有关的问题.与任何制药剂一样,其使用应当以临床证据和监管批准为指导,确保患者的安全性和有效性.

英文名称Aluminium Hydroxide 2-(4-Chlorophenoxy)-2-Methylpropanoate (1:1:2 )
中文名称对氯苯氧异丁酸
IUPAC名称bis((2-(4-chlorophenoxy)-2-methylpropanoyl)oxy)(l3-oxidanyl)aluminum
其它别名ALUMINUM CLOFIBRATE; aluminium clofibrate; ALUFIBRATE; Alluminum; alfibrate; 4-CHLOROPHENOXY-ISO-BUTYRCC ACID, 99+%; Atherolip; Bis[2-(p-chlorophenoxy)-2-methylpropionic acid]hydroxyaluminum salt
CAS编号24818-79-9
MFCD编号:MFCD00865735
EINECS号:246-477-0
FDA UNII编号:56203T2K2X
分子式:C20H20AlCl2O7分子量:470.25
产品CID: 1199660
产品分类原料药 → 循环系统用药 → 调节血脂药

相似结构搜索
InChIKey: USWVMPGQVYZHCA-UHFFFAOYSA-K
InChI=1S/2C10H11ClO3.Al.H2O/c2*1-10(2,9(12)13)14-8-5-3-7(11)4-6-8;;/h2*3-6H,1-2H3,(H,12,13);;1H2/q;;+3;/p-3
计算化学: 氢键受体数7.0氢键供体数1.0可旋转键数4.0

物理性质

熔点120-123 °C
沸点324.1 °C at 760mmHg
闪点149.8 °C
密度3>g/ cm3
PSA:121.78
LogP:2.6553
外观形态固体-粉末
储存条件Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
产品应用该化合物是一种硫酸盐,是一种过氧化物扩散剂.

MSDS等安全信息

安全声明S24/25

合成工艺路线路线简述

📜氯贝酸,三氯化铝,Sodium Hydroxide 以97%的收率获得
参考文献:Han Hui Hwan; Kim Yong Sun; Rim Ok Son,Choson Minchuchu Inmin Konxvaguk Kvaxakvon Txonbo,Kwanagwon Tongvo,1975+
标题:Han Hui Hwan; Kim Yong Sun; Rim Ok Son,Choson Minchuchu Inmin Konxvaguk Kvaxakvon Txonbo,Kwanagwon Tongvo,1975+

海关参考信息

2903919090-氯苯
2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-10035796-B2
优先权日:2014-08-14
标题:Crystalline forms of a BACE inhibitor, compositions, and their use
发明人：KAZAKEVICH IRINA; TRZASKA SCOTT; FENG TAO
权利人:MERCK SHARP & DOHME
摘要:The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an AÎ² pathology and/or a symptom or symptoms thereof. Non-limiting examples of such AÎ² pathologies, including Alzheimer's disease, are disclosed herein.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y. Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate. Cancer Lett. 1990 Aug;53(1):33-8.